Evaluating the local differences in iron accumulation in the deep gray matter of the brain using a special magnetic resonance imaging (MRI) technique, may help identify multiple sclerosis (MS) patients at greater risk for disease progression and disability, a study reports.
The study “Brain Iron by Using Quantitative MRI Is Associated with Disability in Multiple Sclerosis” was published in the journal Radiology.
Measuring brain’s atrophy (shrinkage) is currently used as a predictor of cognitive and physical disability in MS, but assessing these changes in the brain is a long-term task.
“Brain atrophy takes a long time to see,” Robert Zivadinov, MD, PhD, said in a press release. Zivadinov is professor of neurology at the Jacobs School of Medicine and Biomedical Sciences at the University at Buffalo.
“We need an earlier measure of who will develop MS-related disability,” Zivadinov added.
A growing number of studies are investigating the role of iron in MS, its accumulation in white matter and gray matter, and potential damage. However, how iron accumulation in different regions of the brain correlate with MS is still poorly understood.
“It is known that there is more iron in the deep gray matter structures in MS patients, but also we’ve seen in recent literature that there are regions where we find less iron in the brains of these patients,” Zivadinov said.
Together with colleagues, Zivadinov used a recently developed MRI technique, called quantitative susceptibility mapping, to measure the levels of iron accumulation in different areas of the brain in MS patients compared to healthy controls.
They focused on the deep gray matter of the brain and its different regions, including the thalamus and the basal ganglia. The thalamus relays sensory and motor signals into the cerebral cortex, and the basal ganglia is a group of structures responsible primarily for motor control.
“Although literature data consistently show higher iron content in other deep gray matter structures results are more contradictory with respect to the thalamus. Some studies show higher iron content, whereas others report lower iron load,” researchers wrote.
Compared to controls, MS patients showed an increased accumulation of iron in the basal ganglia — measured separately in each sub-structure of the gland, namely the caudate, putamen, and globus pallidus — but levels were lower in the thalamus.
Moreover, lower iron levels in the thalamus correlated with longer disease duration, higher disability degree and disease progression, namely in SPMS. Increased disability also was associated with increased iron accumulation in the globus pallidus, specifically.
These correlations were maintained after researchers adjusted the data for the differences in brain volume of the participants.
“In this large cohort of MS patients and healthy controls, we have reported, for the first time, iron increasing in the basal ganglia but decreasing in thalamic structures,” said Zivadinov. “Iron depletion or increase in several structures of the brain is an independent predictor of disability related to MS.”
Overall, the team concluded that monitoring iron accumulation in the brain may help identify MS patients at greater risk for developing physical disability. The team also suggested that iron levels may be used as a potential readout in clinical trials testing experimental MS therapies.